Biohaven aims to raise $250M; Activist investor’s stake in Galapagos exceeds 10%

Plus, news about IN8bio, Sanofi, Vicore Pharma, Cartherics, Zephyrm Bioscience, Tharimmune and Intract Pharma:

Biohaven’s $250M offering: The move comes after Biohaven announced Monday that …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Clinical Data Abstractors Overburdened by Manual Tasks

What You Should Know: – A new survey conducted by Carta Healthcare reveals a critical issue within the healthcare industry: the overwhelming burden placed on

August 14, 2024

Once-Rejected Drug Now FDA Approved for CKD-Related Anemia

The FDA approved vadadustat (Vafseo) for chronic kidney disease (CKD)-related anemia in adults who have been on dialysis for at least 3 months, developer Akebia

March 29, 2024

Longer Use of ADHD Meds May Boost Heart Risk

Longer use of attention deficit-hyperactivity disorder (ADHD) medication was associated with an increased risk of cardiovascular disease, particularly hypertension and arterial disease, a nested case-control

November 23, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.